Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50-70% of malignant melanomas 1 . Pre-clinical studies have demonstrated that the B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma 2-6 -an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials [7] [8] [9] . However, clinical responses to targeted anticancer therapeutics are frequently confounded by de novo or acquired resistance [10] [11] [12] . Identification of resistance mechanisms in a manner that elucidates alternative 'druggable' targets may inform effective long-term treatment strategies 13 . Here we expressed 600 kinase and kinase-related open reading frames (ORFs) in parallel to interrogate resistance to a selective RAF kinase inhibitor. We identified MAP3K8 (the gene encoding COT/Tpl2) as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines. COT activates ERK primarily through MEK-dependent mechanisms that do not require RAF signalling. Moreover, COT expression is associated with de novo resistance in B-RAF(V600E) cultured cell lines and acquired resistance in melanoma cells and tissue obtained from relapsing patients following treatment with MEK or RAF inhibitors. We further identify combinatorial MAPK pathway inhibition or targeting of COT kinase activity as possible therapeutic strategies for reducing MAPK pathway activation in this setting. Together, these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies.
To identify kinases capable of circumventing RAF inhibition, we assembled and stably expressed 597 sequence-validated kinase ORF clones representing ,75% of annotated kinases (Center for Cancer Systems Biology (CCSB)/Broad Institute Kinase ORF Collection) in A375, a B-RAF(V600E) malignant melanoma cell line that is sensitive to the RAF kinase inhibitor PLX4720 14 (Fig. 1a , b, Supplementary  Table 1 and Supplementary Fig. 2 ). ORF-expressing cells treated with 1 mM PLX4720 were screened for viability relative to untreated cells and normalized to an assay-specific positive control, MEK1(S218/ 222D) (MEK1 DD ) 15 (Supplementary Table 2 and summarized in Supplementary Fig. 1 ). Nine ORFs conferred resistance at levels exceeding two standard deviations from the mean ( Fig. 1b and Supplementary   Table 2 ) and were selected for follow-up analysis ( Supplementary Fig. 3 ). Three of the nine candidate ORFs were receptor tyrosine kinases, underscoring the potential of this class of kinases to engage resistance pathways. Resistance effects were validated and prioritized across a multi-point PLX4720 drug concentration scale in the B-RAF(V600E) cell lines A375 and SKMEL28. The Ser/Thr MAP kinase kinase kinases (MAP3Ks) MAP3K8 (COT/Tpl2) and RAF1 (C-RAF) emerged as top candidates from both cell lines; these ORFs shifted the PLX4720 halfmaximal growth inhibitory concentration (GI 50 ) by 10-600-fold without affecting viability ( Supplementary Table 3 and Supplementary Figs 4 and 5). Both COT and C-RAF reduced sensitivity to PLX4720 in multiple B-RAF(V600E) cell lines ( Fig. 1c ) confirming the ability of these kinases to mediate resistance to RAF inhibition.
Next, we tested whether overexpression of these genes was sufficient to activate the MAPK pathway. At baseline, COT expression increased ERK phosphorylation in a manner comparable to MEK1 DD , consistent with MAP kinase pathway activation ( Fig. 2a and Supplementary Fig. 6 ). Overexpression of wild-type COT or C-RAF resulted in constitutive phosphorylation of ERK and MEK in the presence of PLX4720, whereas kinase-dead derivatives had no effect ( Fig. 2a and Supplementary Fig. 7 ). Based on these results, we proposed that COT and C-RAF drive resistance to RAF inhibition predominantly through re-activation of MAPK signalling. Notably, of the nine candidate ORFs from our initial screen, a subset (three) did not show persistent ERK/MEK phosphorylation following RAF inhibition, suggesting MAPK pathway-independent alteration of drug sensitivity ( Supplementary Fig. 8 ).
Several groups have shown that C-RAF activation and heterodimerization with B-RAF constitute critical components of the cellular response to B-RAF inhibition [16] [17] [18] [19] . In A375 cells, endogenous C-RAF-B-RAF heterodimers were measurable and inducible following treatment with PLX4720 ( Supplementary Fig. 9 ). However, endogenous C-RAF phosphorylation at S338-an event required for C-RAF activationremained low ( Supplementary Fig. 9 ). In contrast, ectopically expressed C-RAF was phosphorylated on S338 ( Supplementary Fig. 9 ) and its PLX4720 resistance phenotype was associated with sustained MEK/ ERK activation ( Fig. 2a , Supplementary Fig. 9 ). Moreover, ectopic expression of a high-activity C-RAF truncation mutant (C-RAF(W22)) was more effective than wild-type C-RAF in mediating PLX4720 resistance and ERK activation ( Supplementary Fig. 10 ), further indicating that elevated C-RAF activity may direct resistance to this agent. Consistent with this model, oncogenic alleles of NRAS and KRAS conferred PLX4720 resistance in A375 cells ( Fig. 2b) and yielded sustained C-RAF(S338) and ERK phosphorylation in the context of drug treatment ( Fig. 2c ). Thus, although genetic alterations that engender C-RAF activation (for example, oncogenic RAS mutations) tend to show mutual exclusivity with B-RAF(V600E) mutation, such co-occurring events 20,21 might be favoured in the context of acquired resistance to B-RAF inhibition.
To investigate the role of COT in melanoma, we first determined its expression in human melanocytes. We found that primary immortalized melanocytes (B-RAF wild-type) expressed COT ( Fig. 2d ), although ectopic B-RAF(V600E) expression reduced MAP3K8 mRNA levels (Supplementary Fig. 11 ) and rendered COT protein undetectable ( Fig. 2d ). Conversely, whereas ectopically expressed COT was only weakly detectable in A375 cells ( Fig. 2a, e ), short hairpin RNA (shRNA)-mediated depletion of endogenous B-RAF(V600E) caused an increase in COT protein levels that correlated with the extent of B-RAF knockdown ( Fig. 2e ). Moreover, treatment of COT-expressing A375 cells with PLX4720 led to a dose-dependent increase in COT protein ( Fig. 2a ) without affecting ectopic MAP3K8 mRNA levels ( Supplementary  Fig. 11 ). Thus, oncogenic B-RAF may antagonize COT expression largely through altered protein stability ( Fig. 2a, d , e and Supplementary Fig. 11 ), and B-RAF inhibition may potentiate the outgrowth of COT-expressing cells during the course of treatment. Notably, neither C-RAF nor B-RAF alone or in combination was required for ERK phosphorylation in the context of COT expression, even in the presence of PLX4720 ( Fig. 2e, f and Supplementary Fig. 12 ), suggesting that COT expression is sufficient to induce MAP kinase pathway activation in a RAF-independent manner.
We predicted that cell lines expressing elevated COT in a B-RAF(V600E) background should show de novo resistance to PLX4720 treatment. To identify such instances, we screened a panel of cell lines for evidence of MAP3K8 copy number gains coincident with the B-RAF(V600E) mutation. Of 534 cell lines that had undergone copy number analysis and mutation profiling, 38 cell lines (7.1%) contained the B-RAF(V600E) mutation. Within this subgroup, two cell lines-OUMS-23 (colon cancer) and RPMI-7951 (melanoma)-also showed evidence of chromosomal copy gains spanning the MAP3K8 locus ( Fig. 3a and Supplementary Fig. 13 ) and robust COT protein expression ( Fig. 3b and Supplementary Fig. 14) . We also screened a panel of melanoma short-term cultures for COT protein expression. Only one of these lines expressed COT: M307, a short-term culture derived from a B-RAF(V600E) tumour that developed resistance to allosteric MEK inhibition following initial disease stabilization 15 (Fig. 3c ). All three cell lines were refractory to PLX4720 treatment, with GI 50 values in the range of 8-10 mM (Fig. 3d ), and showed sustained ERK phosphorylation in the context of B-RAF inhibition (Fig. 3e, f ). OUMS-23 and RPMI-7951 are MAPK pathway inhibitor-naive cell lines, implying that COT may confer de novo resistance to RAF inhibition (a phenomenon observed in ,10% of B-RAF(V600E) melanomas 7 ).
Next, we examined COT expression in the context of resistance to the clinical RAF inhibitor PLX4032 by obtaining biopsy material from three patients with metastatic, B-RAF(V600E) melanoma. Each case consisted of frozen, lesion-matched biopsy material obtained before and during treatment ('pre-treatment' and 'on-treatment'; Fig. 3g and Supplementary Table 4 ); additionally, one sample contained two independent biopsy specimens from the same relapsing tumour site ('postrelapse'; Fig. 3g ). Consistent with the experimental models presented above, quantitative real-time PCR with reverse transcription (qRT-PCR) analysis revealed increased MAP3K8 mRNA expression concurrent with PLX4032 treatment in two of three cases. MAP3K8 mRNA levels were further increased in a relapsing specimen relative to its pre-treatment and on-treatment counterparts ( Fig. 3g, Patient 1 ). An additional, unmatched relapsed malignant melanoma biopsy showed elevated MAP3K8 mRNA expression comparable to levels observed in RAF inhibitor-resistant, MAP3K8-amplified cell lines ( Supplementary  Fig. 15 ). This specimen also exhibited robust MAPK pathway activation and elevated expression of B-RAF, C-RAF and COT relative to matched normal skin or B-RAF(V600E) cell lines ( Supplementary Fig.  15 ). Sequencing studies of this tumour revealed no additional mutations in B-RAF, NRAS or KRAS (data not shown). These analyses provided clinical evidence that COT-dependent mechanisms may be operant in at least some PLX4032-resistant malignant melanomas.
To determine if COT might actively regulate MEK/ERK phosphorylation in B-RAF(V600E) cells that harbour naturally elevated COT expression, we introduced shRNA constructs targeting MAP3K8/COT into RPMI-7951 cells. Depletion of COT suppressed RPMI-7951 viability ( Supplementary Fig. 16 ) and decreased ERK phosphorylation (Fig. 3h) , implying that targeting COT kinase activity might suppress MEK/ERK phosphorylation in cancer cells with COT overexpression or amplification. Treatment of RPMI-7951 cells with a small molecule COT kinase inhibitor 22 
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MEK and ERK phosphorylation, providing additional evidence that COT contributes to MEK/ERK activation in these cells (Fig. 3i ). We then considered whether COT-expressing cancer cells remain sensitive to MAPK pathway inhibition at a target downstream of COT or RAF. Here, we queried the OUMS-23 and RPMI-7951 cell lines for sensitivity to the MEK1/2 inhibitor CI-1040. Interestingly, both cell lines were refractory to MEK inhibition ( Fig. 4a ) and displayed sustained ERK phosphorylation even at 1 mM CI-1040 ( Fig. 4b ). Ectopic COT expression in A375 and SKMEL28 cells also conferred decreased sensitivity to the MEK inhibitors CI-1040 and AZD6244, suggesting that COT expression alone was sufficient to induce this phenotype (Fig. 4c, d and Supplementary Fig. 17 ). Similar to results observed with pharmacological MEK inhibitors, MEK1/2 knockdown only modestly suppressed COT-mediated ERK phosphorylation in A375 cells ( Supplementary Fig. 18 ). In accordance with prior observations 25 , these data raised the possibility that COT may activate ERK through MEK-independent as well as MEK-dependent mechanisms. To test this hypothesis directly, we performed an in vitro kinase assay using recombinant COT and ERK1. Indeed, recombinant COT induced pThr 202/Tyr 204 phosphorylation of ERK1 in vitro ( Supplementary  Fig. 18 ), indicating that in certain contexts COT expression may potentiate ERK activation in a MEK-independent manner.
In experimental models, the use of RAF and MEK inhibitors in combination can override resistance to single agents 15 . We therefore reasoned that combined RAF/MEK inhibition might circumvent COT-driven resistance. In the setting of ectopic COT expression, exposure to AZD6244 or CI-1040 in combination with PLX470 (1 mM each) reduced cell growth and pERK expression more effectively than did single-agent PLX4720, even at concentrations of 10 mM (Fig. 4e, f and Supplementary Fig. 19 ). These data underscore the importance of this pathway in B-RAF(V600E) tumour cells and support earlier findings 15 that dual B-RAF/MEK inhibition may help circumvent resistance to RAF inhibitors.
B-RAF mutations are found in ,8% of all cancers and at high frequencies in malignant melanoma, colon and thyroid cancers 1 .
The clinical promise of selective RAF inhibitors has widespread ramifications for patient treatment, yet single-agent targeted therapy is almost invariably followed by relapse due to acquired drug resistance. Our results suggest that ORF-based, systematic functional screening may offer a powerful means to identify clinically relevant resistance mechanisms that also specify novel treatment strategies. In particular, resistance to RAF inhibition can be achieved by multiple MAP3Kdependent mechanisms of MEK/ERK reactivation but might be intercepted through combined therapeutic modalities for MAPK pathway inhibition (for example, RAF/MEK or RAF/COT combinations). Future systematic drug resistance studies may be expanded to a genome scale that encompasses many compounds, thereby enabling comprehensive identification of both therapy-specific resistance genes and drug targets of novel therapeutics.
METHODS SUMMARY
The arrayed, lentiviral ORF screen was performed as described previously 26 . Effects of individual ORFs on drug resistance were determined by measuring differential viability (ratio of raw viability in 1 mM PLX4720 over control) and subsequent normalization to an assay-specific positive control, MEK1 DD . Secondary screens were performed with the top nine candidate ORFs in 96-well format in A375 and SKMEL28 cells. Prioritization was accomplished via generation of a GI 50 for each ORF across a multi-point PLX4720 concentration range in both cell lines. The effects of identified resistance ORFs on MAPK pathway activation were demonstrated using both biochemical and cell biological approaches. Cell line copy number data was obtained as previously described 27 . Detailed descriptions of all procedures are included in Methods. expressing indicated ORFs following treatment with DMSO or 1 mM of PLX4720, RAF265, CI-1040 or AZD6244. e, Viability of A375 expressing the indicated ORFs and treated with DMSO, PLX4720 (concentration indicated) and PLX4720 in combination with CI-1040 or AZD6244 (all 1 mM). Error bars represent the standard deviation (n 5 6). f, ERK phosphorylation in A375 expressing indicated ORFs following treatment with DMSO, PLX4720 (1 mM) or PLX4720 in combination with CI-1040 or AZD6244 (all 1 mM).
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